Skip to main content
Equibles

4569 · KYORIN Pharmaceutical Co., Ltd. · Financials

Use 4569 with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research 4569.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
1,080 JPY +4 (+0.37%) At close · Nov 13
Rebalance outlook locked
Market Cap
62.04B JPY
Shares
57.45M
Volume · Nov 13 116.6K Avg daily vol (3M) 215.73K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
126.26B -2.9%
FY2026 Revenue FY2022–FY2026
Net Income
3.45B -62.1%
FY2026 Net Income FY2022–FY2026
Gross Margin
40.89% -4.9pp
FY2026 Gross Margin FY2022–FY2026
Operating Margin
2.83% -6.8pp
FY2026 Operating Margin FY2022–FY2026
Operating Cash Flow
6.38B +82%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2026 FY2025 FY2024 FY2023 FY2022
JPY 126.26B 130.09B 119.53B 113.27B 105.53B
JPY 74.63B 70.55B 68.12B 63.1B 56.09B
JPY 51.62B 59.54B 51.41B 50.17B 49.44B
JPY 3.57B 12.57B 6.01B 5.12B 5.01B
JPY 4.45B 12.77B 7.02B 6.91B 5.22B
JPY 1B 3.68B 1.7B 2.18B 1.28B
JPY 3.45B 9.09B 5.32B 4.72B 3.93B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 16.11B in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.